CoChat
Sign Up
Cited by 796Inflammatory mediators and NSAID effectsAntiplatelet Therapy and Cardiovascular DiseasesMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Low-Dose Aspirin in the Primary Prevention of Cancer: The Women’s Health Study: A Randomized Controlled Trial

Cook, Nancy R., Lee, I-Min, Gaziano, J. Michael, Gordon, David, Ridker, Paul M, Manson, JoAnn E., Hennekens, Charles H., Buring, Julie E.·2005·JAMA
DOI 10.1001/jama.294.1.47
Open this paper in CoChat — free account

Abstract

CONTEXT: Basic research and observational evidence as well as results from trials of colon polyp recurrence suggest a role for aspirin in the chemoprevention of cancer. OBJECTIVE: To examine the effect of aspirin on the risk of cancer among healthy women. DESIGN, SETTING, AND PARTICIPANTS: In the Women's Health Study, a randomized 2 x 2 factorial trial of aspirin and vitamin E conducted between September 1992 and March 2004, 39 876 US women aged at least 45 years and initially without previous history of cancer, cardiovascular disease, or other major chronic illness were randomly assigned to receive either aspirin or aspirin placebo and followed up for an average of 10.1 years. INTERVENTION: A dose of 100 mg of aspirin (n=19 934) or aspirin placebo (n=19 942) administered every other day. MAIN OUTCOME MEASURES: Confirmed newly diagnosed invasive cancer at any site, except for nonmelanoma skin cancer. Incidence of breast, colorectal, and lung cancer were secondary end points. RESULTS: No effect of aspirin was observed on total cancer (n = 2865; relative risk [RR], 1.01; 95% confidence interval [CI], 0.94-1.08; P = .87), breast cancer (n = 1230; RR, 0.98; 95% CI, 0.87-1.09; P = .68), colorectal cancer (n = 269; RR, 0.97; 95% CI, 0.77-1.24; P = .83), or cancer of any other site, with the exception of lung cancer for which there was a trend toward reduction in risk (n = 205; RR, 0.78; 95% CI, 0.59-1.03; P = .08). There was also no reduction in cancer mortality either overall (n = 583; RR, 0.95; 95% CI, 0.81-1.11; P = .51) or by site, except for lung cancer mortality (n = 140; RR, 0.70; 95% CI, 0.50-0.99; P = .04). No evidence of differential effects of aspirin by follow-up time or interaction with vitamin E was found. CONCLUSIONS: Results from this large-scale, long-term trial suggest that alternate day use of low-dose aspirin (100 mg) for an average 10 years of treatment does not lower risk of total, breast, colorectal, or other site-specific cancers. A protective effect on lung cancer or a benefit of higher doses of aspirin cannot be ruled out.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.294.1.47

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

1 of the 39 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

See all 796

Related

See all

Metadata

Authors
Cook, N. R., Lee, I.-M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Cook, Nancy R.
ORCID
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2005-07-06
Volume
294
Issue
1
Pages
47
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.294.1.47
OpenAlex
W2051700726
Cited by
796
References
39
Citations by year
2026: 10 · 2025: 12 · 2024: 15 · 2023: 19 · 2022: 20 · 2021: 22 · 2020: 33 · 2019: 22 · 2018: 29 · 2017: 28 · 2016: 43 · 2015: 44 · 2014: 60 · 2013: 58 · 2012: 64
FWCI
39.12
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01hl043851-10)
  • National Heart, Lung, and Blood Institute (HL43851)
  • National Cancer Institute (CA-47988, R01CA047988)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
low-dose aspirin, chemoprevention, primary cancer prevention, cancer incidence, breast cancer, colorectal cancer, lung cancer, cancer mortality, Women's Health Study, non-melanoma skin cancer, vitamin E, healthy women, nonsteroidal anti-inflammatory drugs, bleeding risk, cardiovascular risk
MeSH terms
Aspirin, Double-Blind Method, Drug Administration Schedule, Female, Humans, Middle Aged, Neoplasm Invasiveness, Neoplasms, Risk Factors, Incidence, Cyclooxygenase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review